

NATtrol™ SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock

PRODUCT DESCRIPTION:

NATtrol™ SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock* is formulated with purified, intact viral particles. that have been chemically modified to render them non-infectious and refrigerator stable. Each vial contains 1.0 mL of NATtrol™ SARS-CoV-2 Variant B.1.351 stock in a proprietary matrix at the target concentration listed in Table 1.

*Pat.:http://www.zeptometrix.com/patent-information/

INTENDED USE:

 NATtrol™ SARS-CoV-2 Variant B.1.351 stock is designed to evaluate the performance of nucleic acid tests for determination of the presence of SARS-CoV-2 Variant B.1.351 RNA. NATtrol™ SARS-CoV-2 Variant B.1.351 stock enables laboratories to monitor test variation, lot-to-lot test kit performance, operator variation, and can provide assistance in identifying random or systemic error.

WARNINGS AND PRECAUTIONS:

- NATtrol™ inactivation was carried out on SARS-CoV-2 Variant B.1.351 stock used to formulate the product. The inactivation was verified in a standard microbiological growth protocol.
- This product contains inactivated microorganisms and materials of human and animal origin. Safe practices suggest that the controls be considered potentially infectious and to use Universal Precautions when handling.
- Refer to CDC guidelines and local regulations for handling and disposal.
- The matrix used in the manufacture of this product is treated with 0.09% sodium azide. It was manufactured from Human Serum Albumin that has been tested and found to be non-reactive at the donor level for HIV-1/HIV-2 Antibody, HBsAg and HCV Antibody by FDA licensed donor screening test methods. All materials are also tested for HIV-1 and HCV by FDA approved Nucleic Acid Test (NAT) methods.
- Heat inactivated Fetal Bovine Serum used in the manufacture of this product meets applicable USDA requirements for abattoir sourced animals, traceability and country of origin. The materials were collected at USDA licensed establishments or legally imported from countries recognized by the USDA as negligible or controlled for risk for Bovine Spongiform Encephalopathy (BSE) and other exotic disease agents. Donor animals were inspected ante and post mortem at the abattoir as required by the USDA.
- Do not use past the expiration date on the label.
- To avoid cross-contamination, use separate pipette tips for all materials.

RECOMMENDED STORAGE:

 NATtrol™ SARS-CoV-2 Variant B.1.351 Stock should be stored at 2-8°C.

INSTRUCTIONS FOR USE:

- Mix vial vigorously for at least 5 secs.
- Process according to manufacturer's instructions for sample to result assays.
- Extract nucleic acid prior to use in downstream assays that are not sample to result.

LIMITATION:

- FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES
- Quality control materials should be used in accordance with local, state, federal, and accreditation requirements.
- This product is not intended to replace the manufacturer's controls provided with the assay.

EXPECTED RESULTS:

- Each laboratory must evaluate the product and establish their own acceptance criteria.
- Virus information and target level listed in table below.

TABLE 1:

Catalog Number	Virus/Strain	Target Concentration
NATSARS(COV2-SA)-ST	SARS-CoV-2 Variant B.1.351 (Isolate: South_Africa/KRISP- K005325/2020) ¹	1,000,000 copies/mL ²

¹ This reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate hCoV-19/England/204820464/2020, NR-54000, contributed by Bassam Hallis.

PINATSARS(COV2-SA)-ST

Revision: 00

Effective Date: 05/12/2021

REF	Catalog Number	X	Temperature Limitation
LOT	Batch Code	₽	Expiration Date
RUO	For Research Use Only	€	Biological Risk

² Quantitation based on in-house RT-PCR assay targeting N gene region. Quantitation standard assigned copies/mL by dPCR.